LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin

Shinji Yamada, Satoshi Ogasawara, Mika K. Kaneko, Yukinari Kato

研究成果: Article査読

26 被引用数 (Scopus)

抄録

Human podoplanin (hPDPN), the ligand of C-type lectin-like receptor-2, is involved in cancer metastasis. Until now, many monoclonal antibodies (mAbs) have been established against hPDPN. However, it is still difficult to develop a cancer-specific mAb (CasMab) against hPDPN because the protein sequence of hPDPN expressed in cancer cells is the same as that in normal cells. Herein, we report LpMab-23 of the mouse IgG1 subclass, a novel CasMab against hPDPN. In an immunohistochemical analysis, LpMab-23 reacted with tumor cells of human oral cancer, but did not react with normal cells such as lymphatic endothelial cells (LECs). In contrast, LpMab-17, another anti-hPDPN mAb, reacted with both tumor cells and LECs. Furthermore, flow cytometric analysis revealed that LpMab-23 reacted with hPDPN-expressing cancer cell lines (LN319, RERF-LC-AI/hPDPN, Y-MESO-14/hPDPN, and HSC3/hPDPN) but showed little reaction with normal cells (LECs and HEK-293T), although another anti-hPDPN mAb, LpMab-7, reacted with both hPDPN-expressing cancer cells and normal cells, indicating that LpMab-23 is a CasMab against hPDPN.

本文言語English
ページ(範囲)72-76
ページ数5
ジャーナルMonoclonal antibodies in immunodiagnosis and immunotherapy
36
2
DOI
出版ステータスPublished - 2017 4

ASJC Scopus subject areas

  • 免疫アレルギー学
  • 免疫学

フィンガープリント

「LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル